Hatice Senses Kurukiz
10 June 2022•Update: 11 June 2022
ISTANBUL
One person dies every 37 seconds from venous thromboembolic disease around the world, according to a Turkish biotech company.
Deep vein thrombosis, which affects five to 20 people per 10,000 each year, is a serious disease caused by the formation of blood clots in the deep veins of the lower extremities, INVAMED-RD Global said in a statement.
The most life-threatening component of venous thromboembolism is pulmonary embolism, which occurs when a blood clot breaks off and moves towards the lung through the blood flow.
If the blood clot is large enough, it can stop the blood flow to the lungs by blocking the pulmonary artery, in what can prove fatal for the patient, it said.
It is critical to treat pulmonary embolism as soon as possible in order to avoid potentially fatal complications, explained the company.
It added that clinical studies showed that the INVAMED Dovi ThromboJET Aspiration System, which is used in the treatment of thrombosis, can produce positive results, particularly in the first 14 days.
Rasit Dinc, the company's head, said early diagnosis and treatment of venous thromboembolic disease can save lives.
"The successful results obtained by testing the Dovi ThromboJET Aspiration System, which we have developed in our production campus, on a patient group which is difficult to treat and under a life-threatening situation, show that the disease is preventable as well as fatal," Dinc said.
*Writing by Zehra Nur Duz
